Additionally, circNRIP1 silencing can reduce tumor size in vivo. Mechanistically, inhibition of circNRIP1 attenuated malignant progress of PTC through miR-653-5p/PBX3 axis, which may provide therapeutic target for PTC treatment. The gene discussed is PBX3; the disease is neoplasm.